Paul S. Herendeen

2017 - Valeant Pharmaceuticals International

In 2017, Paul S. Herendeen earned a total compensation of $2.6M as Executive Vice President and Chief Financial Officer at Valeant Pharmaceuticals International, a 92% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$1,590,000
Salary$1,000,000
Other$7,950
Total$2,597,950

Herendeen received $1.6M in non-equity incentive plan, accounting for 61% of the total pay in 2017.

Herendeen also received $1M in salary and $8K in other compensation.

Rankings

In 2017, Paul S. Herendeen's compensation ranked 4,275th out of 14,666 executives tracked by ExecPay. In other words, Herendeen earned more than 70.9% of executives.

ClassificationRankingPercentile
All
4,275
out of 14,666
71st
Division
Manufacturing
1,492
out of 5,748
74th
Major group
Chemicals And Allied Products
427
out of 2,048
79th
Industry group
Drugs
327
out of 1,704
81st
Industry
Pharmaceutical Preparations
262
out of 1,313
80th
Source: SEC filing on March 21, 2018.

Herendeen's colleagues

We found four more compensation records of executives who worked with Paul S. Herendeen at Valeant Pharmaceuticals International in 2017.

2017

William Humphries

Valeant Pharmaceuticals International

Group Chairman

2017

Joseph Papa

Valeant Pharmaceuticals International

Chief Executive Officer

2017

Thomas Appio

Valeant Pharmaceuticals International

Group Chairman

2017

Christina Ackermann

Valeant Pharmaceuticals International

General Counsel

News

You may also like